Loading…
← CockpitCompetitor Analysis › INNOVACAP.NS Innova Captab LimitedOpen in the cockpit ↗

Innova Captab LimitedINNOVACAP.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum strong 73
Mkt cap
$645M
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$989,815
20-day average traded
Fwd P/E
32.2×
forward earnings
ROIC−WACC
+0.6 pp
WACC 11.6%
Hurdle
-4 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · INR₹1,050
1D+1.2%
1W-3.8%
1M+4.8%
3M+0.7%
6M+20.2%
YTD+45.8%
1Y+47.9%
ATR %5.5%
Beta0.31
52w lowhigh22.4% off high

What Innova Captab does

Employees: 2,301

Innova Captab at a glance

Size Innova Captab (INNOVACAP.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $645M, the 755th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,050 on 18 Nov 2026.

Performance Over six months the shares gained 20.2%, against -17.8% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 36.8% over the last twelve months (peer median +10.2%); the operating margin is 12.4% (peer median 9.6%).

Valuation It trades at 32.2× forward earnings against a peer median of 24.9× (4th most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +31%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.6 points above its cost of capital (11.6% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026INNOVACAP.NS 119Peer median 84
Six months, rebased to 100: Innova Captab against the median of its 20 peers (local-currency closes).

Innova Captab financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹18.7B₹16.1B₹12.4B₹10.8B₹9.26B
Revenue growth—+30%+15%+16%—
Gross profit₹4.19B₹2.45B₹2.12B₹1.87B₹1.39B
EBITDA₹2.78B₹2.10B₹1.81B₹1.55B₹1.14B
Net income₹1.69B₹1.43B₹1.27B₹943M₹680M
Free cash flown/a₹341M-₹1.06B-₹1.53B-₹238M
Capital expendituren/a₹683M₹1.72B₹2.87B₹790M
Total debt₹3.55B₹3.44B₹3.38B₹2.45B₹2.37B

Quarterly statements and history in the cockpit →

Innova Captab competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%0005663000164123FDC300878SPARCABUSBCAXANNX688488PHIL301211OLMA6886584105600351ORCHPHARMA002940603567INNOVACAP.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Innova Captab is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%+300%0×50×100×300016688488PHIL6886584105ORCHPHARMA603567INNOVACAP.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Innova Captab is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%3000164123FDC6884884105600351300194002940603567INNOVACAP.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Innova Captab is the large dot.

Innova Captab competitors and peer comparison

How Innova Captab compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Innova Captab against its 20 peers (data as of 18 Nov 2026)
MeasureINNOVACAP.NSPeer medianRank in peer set
1-month return+4.8%-9.2%3rd highest of 21
6-month return+20.2%-17.8%2nd highest of 21
Distance from 52-week high-22.4%-38.7%6th highest of 21
Revenue growth (TTM)+36.8%+10.2%5th highest of 18
Operating margin12.4%9.6%7th highest of 17
Forward P/E32.2×24.9×4th most expensive of 8
Growth the price implies (Req g, 7 yrs)27.1%10.1%3rd most demanding of 10
Growth delivered (Del g)+31.4%+7.9%highest of 10
Hurdle (Req g minus delivered)-4.3 pp+12.0 pp3rd least demanding of 10
ROIC minus cost of capital+0.6 pp-3.9 pp3rd highest of 14
EV / EBITDA22.7×6.2×2nd most expensive of 7
Net debt / EBITDA0.9×-0.8×3rd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%32.2×27.1%+31.4%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%n/an/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%79.7×9.1%+7.9%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%
FDC FDC.NSIndia$653M+3%+10%14%n/a25.2%+10.3%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%n/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%

Questions

Which companies are Innova Captab's closest peers?
The cockpit's peer set: Hainan Haiyao (000566.SZ), Beijing Beilu Pharmaceutical (300016.SZ), Center Laboratories (4123.TWO), FDC (FDC.NS), Zhejiang Wecome Pharmaceutical (300878.SZ), Sun Pharma Advanced Research (SPARC.NS), Arbutus Biopharma (ABUS), Bicara Therapeutics (BCAX).
Is Innova Captab expensive compared with its peers?
On forward p/e it trades at 32.2× against a peer median of 24.9×, 4th most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +31%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Innova Captab stock performed?
Over six months to 18 Nov 2026 the shares returned +20.2% against -17.8% for the median peer; over one year +47.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.